Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2013

Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2013

Feb 2013 Global Markets Direct Lymphoma203 Pages Price :
$ 2000

Global Markets Directs, \'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma. 

Diffuse Large B-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diffuse Large B-Cell Lymphoma.
  • A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diffuse Large B-Cell Lymphoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diffuse Large B-Cell Lymphoma 9
Diffuse Large B-Cell Lymphoma Therapeutics under Development by Companies 11
Diffuse Large B-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Pre-Clinical Stage Products 20
Comparative Analysis 20
Diffuse Large B-Cell Lymphoma Therapeutics - Products under Development by Companies 21
Diffuse Large B-Cell Lymphoma Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Diffuse Large B-Cell Lymphoma Therapeutics Development 26
Bristol-Myers Squibb Company 26
F. Hoffmann-La Roche Ltd. 27
Sanofi-Aventis 28
AstraZeneca PLC 29
Eli Lilly and Company 30
GlaxoSmithKline plc 31
Seattle Genetics, Inc. 32
Celltrion, Inc. 33
Millennium Pharmaceuticals, Inc. 34
Novartis AG 35
Teva Pharmaceutical Industries Limited 36
Cell Therapeutics, Inc. 37
Genmab A/S 38
IMMUNOMEDICS, INC 39
MethylGene Inc 40
Curis, Inc. 41
Telik, Inc. 42
Pharmacyclics, Inc. 43
Memgen, LLC. 44
CureTech Ltd. 45
Cylene Pharmaceuticals, Inc. 46
Helmholtz Zentrum Mnchen, GmbH 47
Shanghai CP Guojian Pharmaceutical Co.,Ltd. 48
PharmaTech International, Inc. 49
Cell>Point 50
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 58
obinutuzumab - Drug Profile 58
enzastaurin hydrochloride - Drug Profile 59
SAR-3419 - Drug Profile 61
brentuximab vedotin - Drug Profile 62
mocetinostat - Drug Profile 65
ibrutinib - Drug Profile 67
bortezomib - Drug Profile 71
ISF-35 - Drug Profile 75
canfosfamide hydrochloride - Drug Profile 77
BMS-936564 - Drug Profile 81
pidilizumab - Drug Profile 82
belinostat + [bortezomib] - Drug Profile 84
bortezomib + vorinostat - Drug Profile 85
everolimus + panobinostat - Drug Profile 86
Therapeutic allogeneic lymphocytes program - Drug Profile 88
buparlisib - Drug Profile 89
Bendamustine + Rituximab - Drug Profile 92
ofatumumab + [cisplatin] + [cytarabine hydrochloride] + [dexamethasone acetate] + Stem Cell Transplant - Drug Profile 93
ofatumumab + [carboplatin] + [etoposide] + [ifosfamide] - Drug Profile 96
Pixantrone + Rituximab - Drug Profile 98
bevacizumab + [cyclophosphamide] + [doxorubicin] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 99
obinutuzumab + [cyclophosphamide] + [doxorubicin] + [prednisone] [INN] + [vincristine sulfate] - Drug Profile 101
enzastaurin hydrochloride + [gemcitabine] + [oxaliplatin] + [rituximab] - Drug Profile 104
Dexamethasone + Etoposide + Vincristine + Doxorubicin + Cyclophosphamide + Rituximab - Drug Profile 106
ofatumumab - Drug Profile 108
ofatumumab - Drug Profile 109
fostamatinib disodium - Drug Profile 113
etoposide + [cyclophosphamide] + [rituximab] + Radioimmunotherapy - Drug Profile 116
veltuzumab + yttrium y 90 epratuzumab tetraxetan - Drug Profile 118
rituximab biosimilar + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 119
DHAP + Rituximab - Drug Profile 121
cytarabine + doxorubicin + Radioimmunotherapy - Drug Profile 122
ofatumumab + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 124
lenalidomide + [rituximab] - Drug Profile 126
CX-5461 - Drug Profile 127
MK-2206 - Drug Profile 129
rituximab biosimilar - Drug Profile 131
Tumor Antigens + Autologous Dendritic Cells - Drug Profile 133
CUDC-907 - Drug Profile 134
bortezomib + [cyclophosphamide] + [doxorubicin] + [prednisone] + [rituximab] + [vincristine sulfate] - Drug Profile 135
ABT-199 - Drug Profile 136
ARN-3015 - Drug Profile 138
rituximab biosimilar + [cyclophosphamide] + [doxorubicin] + [prednisone] + [vincristine sulfate] - Drug Profile 139
SAR-3419 + [rituximab] - Drug Profile 140
Platinum-EC-G - Drug Profile 141
187 Re-EC-G - Drug Profile 142
PCI-32765 + Rituximab + Cyclophosphamide + Doxorubicin + Vincristine + Prednisone - Drug Profile 143
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 145
131I-Rituximab - Drug Profile 146
Belinostat + [Rituximab] + [Zevalin] - Drug Profile 147
BCL-6 Inhibitor - Drug Profile 148
Multiple Lead Series Targeting IRAK4 - Drug Profile 149
ND-2110 - Drug Profile 150
ND-2158 - Drug Profile 152
pecazine - Drug Profile 154
thioridazine - Drug Profile 155
Diffuse Large B-Cell Lymphoma Therapeutics - Drug Profile Updates 156
Diffuse Large B-Cell Lymphoma Therapeutics - Discontinued Products 188
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products 189
Diffuse Large B-Cell Lymphoma - Product Development Milestones 191
Featured News & Press Releases 191

Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 199
Disclaimer 199

List of Table


Number of Products Under Development for Diffuse Large B-Cell Lymphoma, H1 2013 13
Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2013 14
Number of Products under Development by Companies, H1 2013 16
Number of Products under Development by Companies, H1 2013 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 19
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 20
Comparative Analysis by Late Stage Development, H1 2013 21
Comparative Analysis by Mid Clinical Stage Development, H1 2013 22
Comparative Analysis by Early Clinical Stage Development, H1 2013 23
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Development by Companies, H1 2013 (Contd..1) 26
Products under Development by Companies, H1 2013 (Contd..2) 27
Products under Investigation by Universities/Institutes, H1 2013 28
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 29
Bristol-Myers Squibb Company, H1 2013 30
F. Hoffmann-La Roche Ltd., H1 2013 31
Sanofi-Aventis, H1 2013 32
AstraZeneca PLC, H1 2013 33
Eli Lilly and Company, H1 2013 34
GlaxoSmithKline plc, H1 2013 35
Seattle Genetics, Inc., H1 2013 36
Celltrion, Inc., H1 2013 37
Millennium Pharmaceuticals, Inc., H1 2013 38
Novartis AG, H1 2013 39
Teva Pharmaceutical Industries Limited, H1 2013 40
Cell Therapeutics, Inc., H1 2013 41
Genmab A/S, H1 2013 42
IMMUNOMEDICS, INC, H1 2013 43
MethylGene Inc, H1 2013 44
Curis, Inc., H1 2013 45
Telik, Inc., H1 2013 46
Pharmacyclics, Inc., H1 2013 47
Memgen, LLC., H1 2013 48
CureTech Ltd., H1 2013 49
Cylene Pharmaceuticals, Inc., H1 2013 50
Helmholtz Zentrum Mnchen, GmbH, H1 2013 51
Shanghai CP Guojian Pharmaceutical Co.,Ltd., H1 2013 52
PharmaTech International, Inc., H1 2013 53
Cell>Point, H1 2013 54
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Stage and Molecule Type, H1 2013 61
Diffuse Large B-Cell Lymphoma Therapeutics - Drug Profile Updates 160
Diffuse Large B-Cell Lymphoma Therapeutics - Discontinued Products 192
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products 193
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products (Contd..1) 194

List of Chart


Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2013 13
Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 21
Mid Clinical Stage Products, H1 2013 22
Early Clinical Stage Products, H1 2013 23
Pre-Clinical Stage Products, H1 2013 24
Assessment by Monotherapy Products, H1 2013 55
Assessment by Combination Products, H1 2013 56
Assessment by Route of Administration, H1 2013 57
Assessment by Stage and Route of Administration, H1 2013 58
Assessment by Molecule Type, H1 2013 59
Assessment by Stage and Molecule Type, H1 2013 60

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top